Anzeige
Mehr »
Lynx Broker
Login
Samstag, 19.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien
Magisch! Weg frei für die >Milliarden-Chance< im Pennystockmantel!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAZX ISIN: SE0006371126 Ticker-Symbol: 7V3 
Frankfurt
18.10.19
08:02 Uhr
1,358 Euro
+0,010
+0,74 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANTARGIA AB Chart 1 Jahr
5-Tage-Chart
CANTARGIA AB 5-Tage-Chart

Aktuelle News zur CANTARGIA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.10.Cantargia Reports Filing of Opposition Against Cantargia Patent in Europe210STOCKHOLM, Oct. 10, 2019 /PRNewswire/ -- Cantargia AB today announces that an opposition has been filed against one of the European patents in Cantargia's patent family covering antibody...
► Artikel lesen
10.10.CANTARGIA AB: Cantargia reports filing of opposition against Cantargia patent in Europe-
CANTARGIA Aktien jetzt im kostenlosen Demokonto handeln!
04.09.Cantargia Submits Request for pre-IND Meeting on CAN04 With US FDA185STOCKHOLM, Sept. 4, 2019 /PRNewswire/ -- Cantargia AB today announced that a request for a pre-IND meeting with the US FDA has been submitted. The purpose of the meeting is to discuss the...
► Artikel lesen
27.08.Cantargia - CANFOUR study on track, US trial preparations173On 23 August, Cantargia announced fresh preclinical in vivo data on CAN04 in bladder cancer, which suggests an opportunity to explore this indication. The company also recently announced that the CAN04...
► Artikel lesen
26.08.Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology-
23.08.Cantargia Announce Positive Preclinical Data on CAN04 in Bladder Cancer321STOCKHOLM, Aug. 23, 2019 /PRNewswire/ -- Cantargia AB today announce new positive preclinical data which defines a novel additional development opportunity for Cantargias antibody CAN04....
► Artikel lesen
23.08.Cantargia and BioWa Extend Ongoing Collaboration Around the POTELLIGENT Technology332LUND, Sweden, and PRINCETON, NJ, Aug. 23, 2019 /PRNewswire/ -- Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT Technology...
► Artikel lesen
23.08.Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT Technology274Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT Technology for production of Cantargia's antibody drug candidate CAN04, which...
► Artikel lesen
22.08.Cantargia Publishes Half Year Report191LUND, Sweden, Aug. 22, 2019 /PRNewswire/ -- Cantargia AB's ("Cantargia") half year report for the period January until June 2019 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant...
► Artikel lesen
05.07.Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial-
04.07.Cantargia Announce Full Recruitment of CAN04 Monotherapy arm in Ongoing Phase IIa Clinical Trial36STOCKHOLM, July 4, 2019 /PRNewswire/ -- Cantargia's antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR. Here, CAN04 is examined as...
► Artikel lesen
13.06.Cantargia - Full Phase I data presented at ASCO39Cantargia presented full data (n=22) from the Phase I part of the CANFOUR study at ASCO on 2 June 2019. These data (safety, biomarker and early efficacy data) were consistent with the interim data presented...
► Artikel lesen
02.06.Cantargia: Presentation of Phase I Clinical Data on Antibody CAN04 at ASCO61STOCKHOLM, June 2, 2019 /PRNewswire/ -- New phase I clinical data on Cantargia's antibody CAN04 (nidanilimab) were presented today in an oral session at the 2019 ASCO Annual Meeting. Data...
► Artikel lesen
27.05.Annual General Meeting in Cantargia AB (publ)48STOCKHOLM, May 27, 2019 /PRNewswire/ -- Cantargia's Annual General Meeting on 27 May 2019 resolved in accordance with the following: That no dividend would be paid; To discharge...
► Artikel lesen
27.05.Cantargia Publishes Interim Report for First Quarter 201930STOCKHOLM, May 27, 2019 /PRNewswire/ -- Cantargia AB's ("Cantargia") interim report for first quarter 2019 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant...
► Artikel lesen
20.05.Cantargia, Patheon Biologics Sign Supply Agreement-
16.05.Cantargia: Abstract Published for the Oral Presentation of Antibody CAN04 Phase I Data at ASCO28STOCKHOLM, May 15, 2019 /PRNewswire/ -- Cantargia AB today announces that the abstract of the upcoming oral presentation of CAN04 phase I clinical data at the 2019 ASCO Annual Meeting is...
► Artikel lesen
14.05.Cantargia Announces New Pre-clinical Results Showing Consistent Positive Effects of the Antibody CAN04 When Combined with Platinum-based Chemotherapies24STOCKHOLM, May 14, 2019 /PRNewswire/ -- Cantargia AB today announces new pre-clinical results from the antibody CAN04 (nidanilimab) in combination with platinum-based chemotherapies. Cantargia...
► Artikel lesen
13.05.Cantargia Signs Agreement With Patheon Biologics B.V. for Production of Antibody CAN0450STOCKHOLM, May 13, 2019 /PRNewswire/ -- Cantargia AB (publ) and Patheon Biologics B.V. (part of ThermoFischer Scientific) have signed an agreement regarding future production of the antibody...
► Artikel lesen
30.04.New Number of Shares and Votes in Cantargia25STOCKHOLM, April 30, 2019 /PRNewswire/ -- The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see...
► Artikel lesen
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1